Trials / Completed
CompletedNCT00705666
Treatment of Patients With Chronic Hepatitis C With PegIntron as Monotherapy or in Combination With Ribavirin (Study P04437)(COMPLETED)
Real Situation Observational Study of VIRAFERONPEG® in Patients With Chronic Hepatitis C
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 789 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
In February 2002, a French Consensus Conference on the management of patients with chronic hepatitis C in France was organized. The jury issued several recommendations on pegylated alpha interferon/ribavirin treatment strategy. Three years after these recommendations, it is of interest to understand the evolution of hepatitis C management in France in real clinical practice. This observational study will permit the identification of patients who are treated and will provide information on the use of PegIntron/ Ribavirin.
Detailed description
To assure a good representation of participants treated for hepatitis C, participants who meet the inclusion criteria will be enrolled on a consecutive basis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Peginterferon alfa-2b (SCH 54031) | Peginterferon alfa-2b as monotherapy or in combination with ribavirin will be administered according to the products' labeling. |
| DRUG | Ribavirin (SCH 18908) | Peginterferon alfa-2b as monotherapy or in combination with ribavirin will be administered according to the products' labeling. |
Timeline
- Start date
- 2006-02-01
- Primary completion
- 2008-07-01
- Completion
- 2008-07-01
- First posted
- 2008-06-26
- Last updated
- 2015-10-02
- Results posted
- 2010-06-24
Source: ClinicalTrials.gov record NCT00705666. Inclusion in this directory is not an endorsement.